At an SPD 2022 47th Annual Meeting poster session, researchers look at gender and age differences in pediatric patients with melanoma.
Publications
Examining the Influence of Residual Disease in Excision after Diagnosis with Partial Biopsy in Melanoma
Ramiscal JAB, Stern SI, Wilson AK, et al. Does Residual Invasive Disease in Wide Local Excision after Diagnosis with Partial Biopsy Technique Influence Survival in Melanoma Matched Pair Analysis of Multicenter Selective Lymphadenectomy Trial I and II. J Am Coll Surg. 2022, in press.
Pembrolizumab Moves Toward EU Approval for Resected Stage IIB/IIC Melanoma
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of pembrolizumab (Keytruda) for use as adjuvant therapy in adult and adolescent patients aged 12 years and older with stage IIB or IIC melanoma following complete resection. Additionally, CHMP recommended expanding the indication for pembrolizumab in advanced unresectable or metastatic and stage III melanoma as adjuvant therapy following complete resection for adolescent patients aged 12 years and older.
EMA adopts positive opinion for Keytruda in melanoma following complete resection
A committee of the European Medicines Agency recommended the approval for expanded use of Keytruda (pembrolizumab) as a standalone therapy for the adjuvant treatment of adults and adolescents aged 12 years and older with stage IIB or IIC melanoma who have undergone complete resection.